Jiaogulan for Blood Sugar Regulation

Research suggests that jiaogulan (Gynostemma pentaphyllum) and its primary active compounds, gypenosides, may support blood sugar regulation through several biological mechanisms, including activation of AMPK and PI3K/AKT signaling pathways, reduction of inflammatory markers in fat and muscle tissue, and improved insulin sensitivity at the cellular level. Studies indicate that these effects have been observed in animal models of type 2 diabetes and high-fat diet-induced metabolic disruption, as well as in cell cultures, with one small human proteomics study finding elevated levels of proteins associated with insulin sensitivity following jiaogulan treatment. The available evidence consists almost entirely of preclinical animal and cell-based studies, with no large-scale human clinical trials, meaning it remains unknown whether these findings translate meaningfully to people. A 2025 review of the literature acknowledged the promising preclinical signals but concluded that well-designed human trials are needed before any firm conclusions about effectiveness in people can be drawn.